$FULC News
Last published 4w ago
- 4w agoBWINFULCPRTHPTCAre BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
- 2mo agoFULCFulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies - FULCRUM THERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Thank you for standing by. Welcome to today's conference call regarding the merger agreement between Fulcrum Therapeutics and Slate Medicines. At this time, all participants are in a l
- 2mo agoFULCFulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine TherapiesGlobeNewswireCombined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate’s lead product candidate, SLTE-1009, is a clinical stage, potentially
- 5mo agoFULCFulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic ReviewGlobeNewswire― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik® (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk profile of pociredir
- 6mo agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 6mo agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026GlobeNewswire― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC)
- 6mo agoFULCFulcrum Therapeutics Appoints Josh Lehrer to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of
- 6mo agoFULCFulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ETGlobeNewswireCAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 8mo agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients
- 8mo agoFULCFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 8mo agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025GlobeNewswire― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction,
- 8mo agoFULCFulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseGlobeNewswire― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as
- 8mo agoFULCFulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseGlobeNewswireCAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of
- 9mo agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 10mo agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 10mo agoFULCFulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of
- 11mo agoFULCFulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireCAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® ("Fulcrum") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of
- 11mo agoFULCFulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® ("Fulcrum") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of
- 11mo agoFULCFulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual MeetingGlobeNewswire― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week
- 11mo agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 11mo agoFULCFulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025GlobeNewswireCAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual MeetingGlobeNewswire― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be
- 1y agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025GlobeNewswire― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the
- 1y agoFULCFulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ETGlobeNewswireCAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025GlobeNewswire― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum)
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients
- 1y agoFULCFulcrum Therapeutics to Present at Upcoming Investor MeetingsGlobeNewswireCAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025GlobeNewswire― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events
- 1y agoFULCFulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseGlobeNewswire― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of
- 1y agoFULCFulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseGlobeNewswireCAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics to Present at Upcoming Medical MeetingsGlobeNewswireCAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics to Participate in Upcoming May ConferencesGlobeNewswireCAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025GlobeNewswire― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg
- 1y agoFULCFulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ETGlobeNewswireCAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients
- 1y agoFULCFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024GlobeNewswire― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in
- 1y agoFULCFulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ETGlobeNewswireCAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with
- 1y agoFULCFulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics to Participate in Upcoming December ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
- 1y agoFULCFulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoFULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024GlobeNewswire― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents, and marketable